🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to researchers.

An International Public Health Issue

The sexually transmitted infection are on the rise worldwide, with data suggesting more than 82 million new cases each year. Notably increased rates are seen in the African continent and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the face of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone signifies a huge turning point in the treatment of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Results and Worldwide Availability

As per data detailed in a major medical journal, zoliflodacin eradicated over nine in ten of uncomplicated infections. This puts it on an comparable level with the typical regimen, which uses two antibiotics. The study included over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in many regions with limited resources.

Doctors on the front lines have voiced positive views. The availability of a one-pill regimen such as this is described as a "revolutionary step" for managing the epidemic. This is deemed vital to lessen the impact of the illness for patients and to prevent the spread of untreatable gonorrhoea globally.